Want to see HK:0512 full AI Analyst Report?
Top Page
Grand Pharmaceutical Group Limited
(0512)
Select Model
Select Model
Rating:58Neutral
Price Target:
HK$4.50
â–¼(-15.41% Downside)
Action:Reiterated
Date:10/03/26
The score is driven primarily by acceptable but weakening financial performance—especially the sharp 2025 margin compression and reduced free-cash-flow conversion—combined with clearly bearish technical positioning (below major moving averages and negative MACD). Valuation is a relative support due to a moderate P/E and a ~3.5% dividend yield, but it does not fully offset the recent deterioration in profitability/cash flow and the downtrend.
Positive Factors
Steady revenue growth
Continued revenue growth indicates resilient demand across the company’s pharmaceutical and medical-product portfolio. Maintaining top-line expansion provides a foundation for scale, supports ongoing commercialization investment, and can help preserve market position despite recent profitability pressure.
Negative Factors
Sharp margin compression
The substantial decline in operating and net margins shows that revenue growth is currently producing less profit. If sustained, weaker profitability would reduce reinvestment capacity, diminish earnings resilience, and make future growth less valuable to shareholders.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady revenue growth
Continued revenue growth indicates resilient demand across the company’s pharmaceutical and medical-product portfolio. Maintaining top-line expansion provides a foundation for scale, supports ongoing commercialization investment, and can help preserve market position despite recent profitability pressure.
Read all positive factors
Grand Pharmaceutical Group Limited (0512) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$15.30B
Dividend Yield3.92%
Average Volume (3M)3.38M
Price to Earnings (P/E)13.4
Beta (1Y)0.71
Revenue Growth7.35%
EPS Growth-45.49%
CountryHK
Employees12,614
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)0.32
Shares Outstanding3,549,571,000
10 Day Avg. Volume3,157,121
30 Day Avg. Volume3,381,141
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)1.62
Price to Sales (P/S)2.24
P/FCF Ratio35.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$8.29Price Target Upside55.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.45
Revenue Forecast (FY)HK$12.81B
Grand Pharmaceutical Group Limited Business Overview & Revenue Model
Company Description
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw mat...
How the Company Makes Money
Grand Pharmaceutical Group Limited makes money primarily by selling pharmaceutical and medical products through its commercialization and distribution channels. Its revenue model is largely product-based: (1) Prescription pharmaceutical sales: rev...
Grand Pharmaceutical Group Limited Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
71
Positive
Cash Flow
56
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.56B | 12.28B | 11.64B | 10.53B | 9.56B | 8.60B |
| Gross Profit | 6.55B | 6.78B | 6.74B | 6.52B | 5.95B | 5.25B |
| EBITDA | 2.33B | 2.35B | 3.39B | 2.97B | 3.09B | 3.10B |
| Net Income | 1.13B | 1.24B | 2.47B | 1.88B | 2.08B | 2.40B |
Balance Sheet | ||||||
| Total Assets | 28.11B | 27.17B | 24.99B | 22.52B | 22.37B | 21.06B |
| Cash, Cash Equivalents and Short-Term Investments | 1.27B | 2.09B | 3.14B | 2.47B | 2.48B | 2.87B |
| Total Debt | 5.05B | 4.72B | 4.44B | 3.40B | 4.48B | 3.65B |
| Total Liabilities | 10.75B | 9.99B | 8.47B | 7.24B | 8.16B | 7.61B |
| Stockholders Equity | 17.26B | 17.02B | 16.47B | 15.16B | 14.14B | 13.39B |
Cash Flow | ||||||
| Free Cash Flow | 838.48M | 774.37M | 1.28B | 1.93B | 245.79M | 1.49B |
| Operating Cash Flow | 1.55B | 1.50B | 1.90B | 2.42B | 1.92B | 2.12B |
| Investing Cash Flow | -1.02B | -952.79M | -2.00B | -515.75M | -2.58B | -1.77B |
| Financing Cash Flow | -444.91M | -795.17M | 29.96M | -1.89B | 464.49M | -333.17M |
Grand Pharmaceutical Group Limited Technical Analysis
Negative
5.32
Price Trends
4.83
Negative
4.97
Negative
5.81
Negative
Market Momentum
-0.15
Positive
31.54
Neutral
9.27
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0512, the sentiment is Negative. The current price of 5.32 is above the 20-day moving average (MA) of 4.59, above the 50-day MA of 4.83, and below the 200-day MA of 5.81, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 31.54 is Neutral, neither overbought nor oversold. The STOCH value of 9.27 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0512.
Grand Pharmaceutical Group Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | HK$12.54B | 9.38 | 25.10% | 5.11% | 15.05% | 20.58% | |
74 Outperform | HK$26.72B | 16.30 | 11.32% | 6.71% | -9.56% | -23.22% | |
68 Neutral | HK$29.12B | 6.18 | 7.92% | 5.17% | 7.94% | 52.83% | |
61 Neutral | HK$23.94B | 13.43 | 8.60% | 3.50% | 14.80% | -2.88% | |
58 Neutral | HK$15.30B | 13.45 | 6.61% | 3.92% | 7.35% | -45.49% | |
57 Neutral | HK$35.32B | 14.74 | 5.57% | 6.71% | 6.00% | -23.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:0512
Grand Pharmaceutical Group Limited
4.31
-3.67
-46.01%
HK:0867
China Medical System Holdings
9.82
-3.24
-24.82%
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
12.86
-4.81
-27.23%
HK:1513
Livzon Pharmaceutical Group
23.18
-4.60
-16.55%
HK:3320
China Resources Pharmaceutical Group Ltd.
4.64
-0.09
-1.86%
HK:1681
Consun Pharmaceutical Group Ltd.
15.25
1.05
7.36%
Grand Pharmaceutical Group Limited Corporate Events
Grand Pharmaceutical Proposes Auditor Switch to Deloitte to Support Overseas Expansion
Oct 22, 2026
Grand Pharmaceutical Group Limited, a Bermuda-incorporated pharmaceutical group listed on the Hong Kong Stock Exchange, is pursuing an overseas expansion strategy and aims to reinforce its financial reporting and governance as its international op...
Grand Pharmaceutical’s Interim Results Highlight Nuclear Medicine Surge and Innovation-Driven Growth
Aug 26, 2026
Grand Pharmaceutical reported steady business growth for the six months ended 30 June 2026, with revenue rising 3.2% year-on-year to about HK$6.39 billion and innovative and barrier products contributing roughly half of total sales. Profit attribu...
Grand Pharmaceutical Schedules Board Meeting to Approve Interim Results
Aug 10, 2026
Grand Pharmaceutical Group Limited has scheduled a board meeting for 26 August 2026 to review and approve the interim results for the six months ended 30 June 2026. The meeting will also address other potential business matters, signaling an upcom...
Grand Pharmaceutical Wins FDA Fast Track Status for Innovative Tumor Imaging Drug
Aug 9, 2026
Grand Pharmaceutical Group has secured U.S. FDA Fast Track Designation for GPN01530-2, a radionuclide-drug conjugate independently developed for diagnosing solid tumors, following earlier approval to conduct Phase I/II clinical trials. The designa...
Grand Pharmaceutical Shifts Bermuda Registered Office and Share Registrar
Jul 31, 2026
Grand Pharmaceutical Group Limited announced an administrative change to its corporate infrastructure, shifting its principal share registrar and registered office address in Bermuda to Richmond House, 12 Par-la-Ville Road, Hamilton HM 08, effecti...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.